Serina Therapeutics (SER) Financial Report Summaries

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

External links

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Bad

New words: assist, disposal, Explanatory, fluctuate, headcount, imputed, insignificant, lab, margin, nonpayment, restraint, Serena, software, subcontractor, systematic, team

Removed: addressed, affiliate, aforementioned, Alameda, allocable, allocate, amortized, appointment, approach, approximately, Article, assert, authorization, awarded, body, bonded, breach, capable, capitalize, carry, cease, circumstance, commenced, competent, comply, consecutive, conservator, consignment, contested, continuously, correct, court, created, criteria, cumulative, custodian, damage, declare, defer, define, destruction, detailed, determination, discharged, dismissal, dismissed, Document, emerging, enforceability, exemption, experimentation, fail, fall, guaranteed, important, incomplete, incorrect, inherently, injunction, innovative, insolvency, instituted, invalid, joint, judicial, Jumpstart, jurisdiction, lien, listing, longer, member, month, negotiated, NIH, official, perfected, personal, petition, practical, proceeding, prohibit, prohibited, real, receiver, receivership, reduced, relief, remedied, remedy, repeated, representation, requirement, requiring, restrictive, retrospective, revoked, satisfied, selling, sequestrator, shareholder, Simplifying, sixty, source, standalone, subjective, sum, superior, suspended, Targeted, theft, thereunder, therewith, trustee, understanding, undismissed, unenforceable, unlawful, unremedied, unstayed, vacated, valid, warranty, withdrawn, withheld, work, writ, writing, written

From filing 10-Q 2024 Q3

Financial report summary

Competition

Ascendis Pharma A/S • Adicet Bio

Management Discussion

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
All information presented in this report is based on our fiscal year. Unless otherwise stated, references to particular years, quarters, months or periods refer to our fiscal years ending December 31 and the associated quarters, months and periods of those fiscal years.
We are a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and pain. Our POZ drug delivery technology is designed to enable certain existing drugs and novel drug candidates to be modified in a way that may provide an increase in efficacy and safety of the resulting polymeric drug conjugate. Our proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Our POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in our product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. We believe that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood.